Interaction of heterogeneous nuclear ribonucleoprotein C1/C2 with a novel cis-regulatory element within p53 mRNA as a response to cytostatic drug treatment

Molecular Pharmacology

Volumn 73, Issue 5, 2008, Pages 1558-1567

  Christian, Kyle J ^a   Lang, Matti A ^a   Raffalli Mathieu, Françoise ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; DACTINOMYCIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN C1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN C2; LUCIFERASE; MESSENGER RNA; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN C; HNRPC PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL NUCLEUS; CODON; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DNA DAMAGE; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE CONSTRUCT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUALITATIVE ANALYSIS; REPORTER GENE; SITE DIRECTED MUTAGENESIS; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; CELL LINE; CHEMISTRY; CONFORMATION; DOWN REGULATION; DRUG EFFECT; GENETICS; METABOLISM; MOLECULAR GENETICS; MOLECULAR WEIGHT; MUTATION; OPEN READING FRAME; PHOSPHORYLATION; PROTEIN TRANSPORT; REGULATORY RNA SEQUENCE; RNA PROBE;

AMINO ACID SEQUENCE; BASE SEQUENCE; BINDING SITES; CELL LINE; CELL NUCLEUS; CISPLATIN; CODON; CYTOPLASM; CYTOSTATIC AGENTS; DACTINOMYCIN; DOWN-REGULATION; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP C; HUMANS; LUCIFERASES; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; MUTATION; NUCLEIC ACID CONFORMATION; OPEN READING FRAMES; ORGAN SPECIFICITY; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; REGULATORY SEQUENCES, RIBONUCLEIC ACID; RNA PROBES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42449086890     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.042507     Document Type: Article

References (40)

1. Achanta G and Huang P (2004) Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res 64:6233-6239.
2. Blagosklonny MV, Demidenko ZN, and Fojo T (2002) Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity. Cell Cycle 1:67-74.
3. Burd CG, Swanson MS, Gorlach M, and Dreyfuss G (1989) Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc Natl Acad Sci U S A 86:9788-9792.
4. Christian K, Lang M, Maurel P, and Raffalli-Mathieu F (2004) Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene. Mol Pharmacol 65:1405-1414.
5. Dreyfuss G, Matunis MJ, Pinol-Roma S, and Burd CG (1993) hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 62:289-321.
6. Fu L and Benchimol S (1997) Participation of the human p53 3′UTR in translational repression and activation following gamma-irradiation. EMBO J 16:4117-4125.
7. Geneste O, Raffalli F, and Lang MA (1996) Identification and characterization of a 44 kDa protein that binds specifically to the 3′-untranslated region of CYP2a5 mRNA: inducibility, subcellular distribution and possible role in mRNA stabilization. Biochem J 313:1029-1037.
8. Green DM, Cotton CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D'Angio GJ, et al. (2007) Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 48:493-499.
9. Hamilton BJ, Nagy E, Malter JS, Arrick BA, and Rigby WF (1993) Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences. J Biol Chem 268:8881-8887.
10. Hauer J, Graubner U, Konstantopoulos N, Schmidt S, Pfluger T, and Schmid I (2007) Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen. Pediatr Blood Cancer 49:852-854.
11. Holcík M, Gordon BW, and Korneluk RG (2003) The internal ribosome entry site-mediated translation of antiapoptotic protein XIAP is modulated by the heterogeneous nuclear ribonucleoproteins C1 and C2. Mol Cell Biol 23:280-288.
12. Jung Y and Lippard SJ (2006) RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase. J Biol Chem 281:1361-1370.
13. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
14. Kattapuram T, Yang S, Maki JL, and Stone JR (2005) Protein kinase CK1α regulates mRNA binding by heterogeneous nuclear ribonucleoprotein C in response to physiologic levels of hydrogen peroxide. J Biol Chem 280:15340-15347.
15. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, and Poirier GG (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976-3985.
16. Kim JH, Paek KY, Choi K, Kim TD, Hahm B, Kim KT, and Jang SK (2003) Heterogeneous nuclear ribonucleoprotein C modulates translation of c-myc mRNA in a cell cycle phase-dependent manner. Mol Cell Biol 23:708-720.
17. Lee HH, Chien CL, Liao HK, Chen YJ, and Chang ZF (2004) Nuclear efflux of heterogeneous nuclear ribonucleoprotein C1/C2 in apoptotic cells: a novel nuclear export dependent on Rho-associated kinase activation. J Cell Sci 117:5579-5589.
18. Lee SY, Park JH, Kim S, Park EJ, Yun Y, and Kwon J (2005) A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-binding proteins in response to DNA double-strand breaks. Biochem J 388:7-15.
19. Ljungman M and Lane DP (2004) Transcription-guarding the genome by sensing DNA damage. Nat Rev Cancer 4:727-737.
20. Ljungman M, Zhang F, Chen F, Rainbow AJ, and McKay BC (1999) Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18:583-592.
21. Lowry OH, Rosenbrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
22. Mansur CP (1997) The regulation and function of the p53 tumor suppressor. Adv Dermatol 13:121-166.
23. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD, and Gorospe M (2003) RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci U S A 100:8354-8359.
24. McAfee JG, Soltaninassab SR, Lindsay ME, and LeStourgeon WM (1996) Proteins C1 and C2 of heterogeneous nuclear ribonucleoprotein complexes bind RNA in a highly cooperative fashion: support for their contiguous deposition on pre-mRNA during transcription. Biochemistry 35:1212-1222.
25. Mills AA (2005) p53: link to the past, bridge to the future. Genes Dev 19:2091-2099.
26. Moll UM, Wolff S, Speidel D, and Deppert W (2005) Transcription- independent pro-apoptotic functions of p53. Curr Opin Cell Biol 17:631-636.
27. Nakielny S and Dreyfuss G (1996) The hnRNP C proteins contain a nuclear retention sequence that can override nuclear export signals. J Cell Biol 134:1365-1373.
28. Perry RP and Kelley DE (1970) Inhibition of RNA synthesis by actinomycin D: characteristic dose-response of different RNA species. J Cell Physiol 76:127-139.
29. Pichard-Garcia L, Gerbal-Chaloin S, Ferrini JB, Fabre JM, and Maurel P (2002) Use of long-term cultures of human hepatocytes to study cytochrome P450 gene expression. Methods Enzymol 357:311-321.
30. Qin LF and Ng IO (2001) Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 172:7-15.
31. Rajagopalan LE, Westmark CJ, Jarzembowski JA, and Malter JS (1998) hnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA. Nucleic Acids Res 26:3418-3423.
32. Ryan KM, Phillips AC, and Vousden KH (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13:332-337.
33. Shen Y and White E (2001) p53-dependent apoptosis pathways. Adv Cancer Res 82:55-84.
34. Shetty S (2005) Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells. Mol Cell Biochem 272:107-118.
35. Spriggs KA, Bushell M, Mitchell SA, and Willis AE (2005) Internal ribosome entry segment-mediated translation during apoptosis: the role of IRES-trans-acting factors. Cell Death Differ 12:585-591.
36. Yang DQ, Halaby MJ, and Zhang Y (2006) The identification of an internal ribosomal entry site in the 5′-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 25:4613-4619.
37. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, and Dawson VL (2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297:259-263.
38. Zhang S, Schlott B, Gorlach M, and Grosse F (2004) DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA helicase II/RNA helicase A and hnRNP proteins in an RNA-dependent manner. Nucleic Acids Res 32:1-10.
39. Zou T, Mazan-Mamczarz K, Rao JN, Liu L, Marasa BS, Zhang AH, Xiao L, Pullmann R, Gorospe M, and Wang JY (2006) Polyamine depletion increases cytoplasmic levels of RNA-binding protein HuR leading to stabilization of nucleophosmin and p53 mRNAs. J Biol Chem 281:19387-19394.
40. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31:3406-3415.